Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who a
Tevogen’s investigational precision T cell product, TVGN-489, is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple precise targets across the entire SARS-CoV-2 genome.The immunocompromised COVID-19 patients who are unable to take or unlikely...
Source: pharmiweb.com